Radiogenomics is the future of treatment response assessment in clinical oncology
- PMID: 29863785
- PMCID: PMC9560777
- DOI: 10.1002/mp.13035
Radiogenomics is the future of treatment response assessment in clinical oncology
Conflict of interest statement
Dr. El‐Naqa and Dr. Napel have no relevant conflicts of interest.
References
-
- Beckman RA, Clark J, Chen C. Integrating predictive biomarkers and classifiers into oncology clinical development programmes. Nat Rev Drug Discovery. 2011;10:735–748. - PubMed
-
- Bradley E. Incorporating biomarkers into clinical trial designs: points to consider. Nature Biotechnol. 2012;30:596–599. - PubMed
-
- Altrock PM, Liu LL, Michor F. The mathematics of cancer: integrating quantitative models. Nat Rev Cancer. 2015;15:730–745. - PubMed
-
- El Naqa I. Perspectives on making big data analytics work for oncology. Methods. 2016;111:32–44. - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
